Clinical trials: Cancer Pains
Moderate-to-severe Chronic Noncancer Pain
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
- Trial name
- NCT02603705
- Testing
- Oxycodone extended-release
- Where
- 39 sites in United States
- Volunteers
- 281 people
- Sponsor
- Egalet Ltd
Uterine Fibroids, Polyps
HOME Study: Hysteroscopic Office Myomectomy Evaluation
The purpose of this study is to demonstrate safety and effectiveness of the MyoSure Tissue Removal System when used by community gynecologists in an office setting for the treatment of patients with symptomatic intrauterine…
- Trial name
- HOME (NCT01152112)
- Testing
- Myomectomy
- Where
- 9 sites in United States
- Volunteers
- 74 people
- Sponsor
- Hologic, Inc.
Cancer, Bowel Dysfunction
Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants…
- Trial name
- NCT00135577
- Testing
- alvimopan
- Where
- 40 sites in United States, Canada and 11 more
- Volunteers
- 67 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Breakthrough Pain
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
Patients treated in Palliative Care Units are potentially fragile patients, especially in our case, which are cancer patients. The management of these patients is usually done from experience, because these patients rarely meet…
- Trial name
- CAVIDIOPAL (NCT02840500)
- Testing
- No intervention
- Where
- 10 sites in Spain
- Volunteers
- 101 people
- Sponsor
- Angelini Farmacéutica
Pain
Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient
This is a single center, open label, randomized, parallel group single dose intravenous (i.v.) administration study. The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.
- Trial name
- NCT01482936
- Testing
- Oxycodone (OxyNorm®) Injection
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Pain, Cancer
A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain
The purpose of this study is to evaluate the efficacy and safety of fentanyl 1-day application (JNS020QD) transdermal patch (patch containing a drug that is put on the skin so the drug can enter the body through the skin) and to…
- Trial name
- NCT00644787
- Testing
- Fentanyl 1-day transdermal patch (Titration Phase), Fentanyl 1-day transdermal patch (Double Blind Phase), Fentanyl 3-day transdermal patch (Double Blind Phase)
- Where
- 43 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Janssen Pharmaceutical K.K.
Bone Metastasis
A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
The study hypotheses is that the proportion of patients experiencing clinically significant pain relief will be at least 30% greater than the proportion experiencing worsening pain.
- Trial name
- NCT01833806
- Testing
- ExAblate MRgFUS
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- InSightec
Pain
Open Label Assessment of Long-Term Safety and Utility
The purpose of this study is to monitor the long-term analgesic effectiveness, safety, and utility of oxymorphone ER for the relief of moderate to severe pain due to cancer.
- Trial name
- NCT00904449
- Testing
- Oxymorphone ER
- Volunteers
- 24 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Neoplasm Metastasis
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.
- Trial name
- NCT00434317
- Testing
- Zoledronic acid
- Where
- 4 sites in Hungary
- Volunteers
- 80 people
- Sponsor
- Novartis
Breakthrough Pain
Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent
In the context of radiotherapy, control of breakthrough pain represents a special challenge. Patients undergoing radiotherapy may experience different situations of pain that may be due to the need to remain immobilized during…
- Trial name
- CAVIDIOR (NCT02836379)
- Testing
- No intervention
- Where
- 11 sites in Spain
- Volunteers
- 79 people
- Sponsor
- Angelini Farmacéutica
Colon Cancer, Post Operative Pain
Propofol With Clonidine and Ketamine Throughout Colon Cancer Surgery
The Study Showed that combining clonidine and ketamine together can increase the likelihood of achieving a sufficient level of anaesthesia while minimizing post-operative discomfort and inflammation.
- Trial name
- NCT05536362
- Testing
- TCI Propofol Injection
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Egymedicalpedia
Cancer, Pain
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain
- Trial name
- NCT01885182
- Testing
- Oxycodone/Naloxone, Oxycodone
- Where
- 28 sites in China
- Volunteers
- 232 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Intractable Cancer Pain
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
The study is a multicenter, open-label Phase 1b single dose escalation safety study for adult subjects with intractable pain associated with cancer in any area below the mid-thoracic level who meet all other eligibility criteria.
- Trial name
- NCT03226574
- Testing
- Resiniferatoxin
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Sorrento Therapeutics, Inc.
Symptomatic Neuroma, Amputation
Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends
This pilot study evaluates the tolerability and feasibility of the Axoguard Large-Diameter Nerve Cap (sizes 5-7 mm) for protecting and preserving terminated nerve endings after limb trauma or amputation when immediate attention…
- Conditions
- Symptomatic Neuroma, Amputation, Chronic Nerve Pain
- Trial name
- REPOSE-XL℠ (NCT04865679)
- Testing
- Axoguard Nerve Cap®
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Axogen Corporation
Pain Management, Cancer Pain
A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain
The purpose of this study is to compare efficacy of pain treatment with ITDD to efficacy of pain treatment with CMM in patients with pancreatic cancer pain.
- Trial name
- NCT02578459
- Testing
- Intrathecal Drug Delivery System, Conventional Medical Management
- Where
- United States
- Sponsor
- Flowonix Medical
Pain, Unspecified Adult Solid Tumor, Protocol Specific
Improving Pain Management in Patients With Nonhematologic Cancer
RATIONALE: A pain assessment and management system for people with cancer may help doctors accurately assess and plan more effective pain treatment for patients who have cancer.
- Trial name
- NCT00036829
- Testing
- pain therapy
- Where
- United States
- Sponsor
- Inflexxion, Inc.
Neoplasm Metastasis, Palliative Care
A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.
- Trial name
- NCT00545129
- Testing
- Tanezumab 10 mg IV
- Where
- 39 sites in United States, Austria and 11 more
- Volunteers
- 59 people
- Sponsor
- Pfizer